<DOC>
	<DOCNO>NCT01367509</DOCNO>
	<brief_summary>This study evaluate Pharmacokinetics MNTX healthy control subject patient mild , moderate , severe renal impairment require hemodialysis .</brief_summary>
	<brief_title>Pharmacokinetics , Safety , Tolerability Methylnaltrexone ( MNTX ) Subjects With Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Body weight &gt; 100 lb . ( &gt; 45 kg ) , body mass index ( BMI ) 1838 kg/m2 , inclusive ( BMI 1830 match reference group ) 2 . For patients/subjects require pharmacotherapy , stable drug regimen , define started new drug change dosage within three ( 3 ) day five ( 5 ) halflives ( whichever longer ) prior administration MNTX concomitant medication must either conformed list approve drug dosage approve sponsor . 3 . Patients normal renal function , demographically comparable patient impaired renal function weight age within range chronic kidney disease ( CKD ) group average match reference group within 10 year 10 kg average CKD 4 . Patients impaired renal function , good general health except illness associate CKD . 1 . Subjects/patients condition possibly affect drug absorption ( eg . Gastrectomy clinically significant diabetic gastroenteropathy ) 2 . Methadone use 3 . Consumption grapefruit grapefruit juice within seven ( 7 ) day prior administration study medication . 4 . Patients require hemodialysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>